---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-024232"
form_type: "8-K"
ticker: "SRTS"
cik: "0001494891"
company_name: "Sensus Healthcare, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:35:42.347313+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensus Healthcare Q1 revenue $10.3M (+237% YoY); net income $0.97/share; launches new product, share buyback

## Summary
- Revenue $10.3M, up 237% YoY; net income $16.1M ($0.97 diluted) vs net loss $1.1M.
- Adjusted EBITDA $16.9M vs $(0.8M); gross margin expanded to 69.1% from 51.6%.
- Sold non-core asset for $15.0M cash, recorded $12.8M gain; launched TransDermal Infusion product.
- Board approved $3.0M share repurchase program; cash balance $32.8M.
- Affirms Q2 and FY 2022 profitability expectations.

## SEC filing metadata
- accession: 0001213900-22-024232
- form_type: 8-K
- ticker: SRTS
- cik: 0001494891
- company_name: Sensus Healthcare, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1494891/000121390022024232/0001213900-22-024232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1494891/000121390022024232/ea159369-8k_sensushealth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-024232
- JSON: https://secwatch.observer/filing/0001213900-22-024232.json
- Plain text: https://secwatch.observer/filing/0001213900-22-024232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.